此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Role of Gut and Skin Microbiota in Alopecia Areata (RGSM-AA-ICS)

2026年7月10日 更新者:Tea Rosovic、Polyclinic GrandMed

The goal of this clinical trial is to learn if fecal microbiota transplantation (FMT) works to treat alopecia areata in adults. It will also learn about the safety of FMT. The main questions it aims to answer are:

  • Can FMT cause hair regrowth?
  • Can FMT modulate immune response? Researchers will compare FMT to a placebo (a look-alike substance that contains no drug) to see if FMT works to treat alopecia areata.

Participants will:

  • Take FMT or a placebo for three consecutive days
  • Follow-up evaluations will be performed at weeks 12, 24, and 48, with repeat clinical scoring, photodocumentation, microbiome analyses, laboratory testing, and quality-of-life assessment.

研究概览

研究类型

介入性

注册 (估计的)

30

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Tea Rosovic, Dermatovenerology specialist
  • 电话号码:+00385913737237
  • 邮箱:tearosovic@gmail.com

学习地点

      • Opatija、克罗地亚
        • Polyclinic GrandMed
        • 接触:
          • Tea Rosovic, Dermatovenerology specialist
          • 电话号码:+00385913737237
          • 邮箱:tearosovic@gmail.com
        • 首席研究员:
          • Tea Rosovic, Dermatovenerology specialist

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Adults aged 18-65 diagnosed with Alopecia Areata (patchy or extensive) up to 10 years
  2. Willingness to adhere to study protocols, including FMT administration via capsules or colonoscopy.
  3. Ability to sign informed consent.
  4. SALT score≥ 20

Exclusion Criteria:

  1. History of gastrointestinal disorders (e.g., IBD, celiac disease).
  2. Recent use of antibiotics, probiotics, or prebiotics (within 2 months).
  3. Pregnant or breastfeeding women of childbearing potential who are unwilling or unable to use an acceptable method of birth control.
  4. Individuals with immunocompromised or immunosuppressed states (e.g., HIV, cancer).
  5. Prior FMT treatment for any condition.
  6. Therapy with new antidepressants or had a change in antidepressant dose within previous 3 months
  7. Serious medical comorbidities(including neurological or phychiatric comorbidities)
  8. Elevated C-reactive protein concentration, abnormal baseline laboratory tests
  9. Severe(anaphylactic) food allergy
  10. Concomitant treatments for AA: topical KS 1 week prior to randomization, topical JAK inhibitor, diphenylcyclopropenone, or other topical immunotherapies within 4 weeks prior to randomization;systemic corticosterids, immunosuppressant, intra-lesional or intra-articular corticosteroid injections, or oral JAK inhibitor within 8 weeks prior to randomization;monoclonal antibody <5 half-lives prior to randomization; probenecid at the time of randomization. Bimatoprost ophtalmic solution was allowed if on stable dose for 8 weeks.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:FMT group
Interventional group
Patients with alopecia areata will recieve FMT or in the 3 capsules for three consecutive days or FMT via colonoscopy
其他名称:
  • 裂变材料
安慰剂比较:Placebo group
This group will recieve placebo capsules or saline via colonoscopy
Patients will recieve three capsules with inert material or saline via colonoscopy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Changes in hair growth- Severity of Alopecia Tool
大体时间:From enrollment to the end of treatment at 48 weeks
The primary success will be a statistically significant difference in hair regrowth between the Fecal Microbiota transplantation (FMT) group and placebo group at weeks 24 and 48, assessed as a binary endpoint (regrowth yes/no) and supported by changes in SALT (Severity of Alopecia Tool) score as a standardized measurement used to quantify scalp hair loss in patients with alopecia areata. The scale ranges from 0 (no hair loss) to 100 (complete scalp hair loss). A clinically meaningful reduction in SALT score (≥50% improvement from baseline) will be considered a strong indicator of therapeutic efficacy.
From enrollment to the end of treatment at 48 weeks
Changes in hair growth- Alopecia Areata Investigator Global Assessment
大体时间:From enrollment to the end of treatment at 48 weeks
The primary success will be a statistically significant difference in hair regrowth between the Fecal Microbiota transplantation (FMT) group and placebo group at weeks 24 and 48, assessed as a binary endpoint (regrowth yes/no) and supported by changes in Alopecia Areata Investigator Global Assessment (AA-IGA) to measure five clinically meaningful gradations of alopecia areata scalp-hair loss that reflects patients' and clinicians' perspectives and expectations of treatment success in alopecia areata treatment studies. The AA-IGA score is based on the patient's SALT score. The scale is numbered from 0, which corresponds to 0% of hair loss (ie, SALT 0), indicating no hair loss, to 4, which corresponds to 95-100% of hair loss (ie, SALT 95-100), indicating very severe hair loss.
From enrollment to the end of treatment at 48 weeks
Changes in hair growth- The Alopecia Areata Scale
大体时间:From enrollment to the end of treatment at 48 weeks
The primary success will be a statistically significant difference in hair regrowth between the Fecal Microbiota transplantation (FMT) group and placebo group at weeks 24 and 48, assessed as a binary endpoint (regrowth yes/no) and supported by changes in The Alopecia Areata Scale (AASc) in wich primary criterion is Severity of scalp hair loss: mild 20% or less, moderate 21-49%, severe 50-100% scalp hair loss. Secondary criteria: is any is present, increase severity rating by one level: noticeable involvement of eyebrows or eyelashes; inadequate response after at least 6 months of treatment; negative impact on psychosocial functioning resulting from AA; diffuse (multifocal) positive hait pull test consistent with pidly progressive alopecia areata.
From enrollment to the end of treatment at 48 weeks
Fecal microbiota transplantation modulation of the gut and skin microbiota
大体时间:From enrollment to the end of treatment at 48 weeks
The primary objective of this proposal is to test the hypothesis that fecal microbiota transplantation (FMT) induces beneficial modulation of the gut and skin microbiota, leading to immunoregulatory effects in patients with alopecia areata (AA). Characterize baseline skin, and colonic mucosal microbiota composition in patients with AA using 16S rRNA sequencing of skin and colon musosa biopsy specimens and assess changes following FMT.
From enrollment to the end of treatment at 48 weeks
Change in T cell subsets from Baseline to 48 weeks
大体时间:From enrollment to the end of treatment at 48 weeks

Before and after Fecal microbiota transplantation patient will be taken 60-80 ml of peripheral blood for:

  • CBC, CRP
  • Flow cytometry analyses: Tumor necrosis factor alfa (TNFɑ), IL-10, IL-18, IFN-γ, IL-15, IL-2 and trichohyalin; CD4+ Th1 lymphocytes, CD8+ cytotoxic T cells, IFN-γ-producing lymphocytes, CXCR3+ T cells, NK cells, ILC1-like innate lymphoid cells, activated T cells expressing CD69 and HLA-DR, and regulatory T cells (CD4+CD25+FOXP3+)
From enrollment to the end of treatment at 48 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2027年2月1日

研究完成 (估计的)

2027年10月1日

研究注册日期

首次提交

2026年6月26日

首先提交符合 QC 标准的

2026年7月10日

首次发布 (实际的)

2026年7月15日

研究记录更新

最后更新发布 (实际的)

2026年7月15日

上次提交的符合 QC 标准的更新

2026年7月10日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • TD25725

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

IPD used in the results publication

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅